We use our in-house expertise in development of therapeutics and in infectious disease plus our extensive partnership network to identify the best cost-effective commercial opportunities for portfolio value growth.
The focus on infectious diseases is timely. The worldwide anti-infectives market is projected to reach an astounding US$111 billion by 2024. Anti-infectives include antivirals, antifungals and antibacterials .
